Downloading...
Download

Cancervaccine

Moderna's Vaccine Spark Hope in Head and Neck Cancer TreatmentIn a significant breakthrough for cancer treatment, Moderna's ( NASDAQ:MRNA ) individualized cancer vaccine, developed in collaboration with Merck, has shown remarkable promise in an early-stage trial targeting head and neck cancer. The encouraging results have ignited a surge in Moderna's stock price and injected fresh optimism into the field of oncology research. The vaccine, mRNA-4157, aims to train the immune system to identify and combat specific mutations present in cancer cells, representing a pioneering approach in personalized cancer therapy. Following its success in treating melanoma, the vaccine has now demonstrated positive responses in patients with head and neck squamous cell carcinoma, a challenging form of cancer. Data presented at the American Association for Cancer Research Annual Meeting showcased the vaccine's efficacy when administered in combination with Merck's Keytruda. The study, involving 22 patients, revealed promising clinical responses, including instances of complete remission. Notably, the combination therapy not only triggered robust immune responses but also exhibited favorable safety profiles, marking a significant milestone in cancer immunotherapy. Jefferies analyst Michael Yee lauded the results, highlighting the potential of Moderna's therapy platform to transcend melanoma and extend its benefits to other cancer types. The data underscore the transformative potential of mRNA-based vaccines in revolutionizing cancer treatment paradigms and offering new hope to patients grappling with advanced malignancies. The positive outcome has bolstered investor confidence in Moderna ( NASDAQ:MRNA ), propelling its shares to a three-month high. This uptrend reflects renewed enthusiasm for the biotech firm's diverse pipeline, which includes groundbreaking vaccines targeting respiratory syncytial virus and other infectious diseases, alongside innovative cancer therapies. Looking ahead, Moderna's collaboration with Merck signals a concerted effort to advance the development of cancer immunotherapies. The initiation of a Phase 3 trial targeting lung cancer underscores the commitment to translating promising preclinical data into clinically meaningful outcomes, to deliver transformative therapies to patients in need. As Moderna ( NASDAQ:MRNA ) continues to pioneer the frontier of mRNA-based therapeutics, the recent success of its cancer vaccine heralds a new era in precision medicine. With further advancements and clinical validations, this innovative approach holds the potential to reshape the landscape of cancer treatment and offer renewed hope for patients battling this devastating disease.
NASDAQ:MRNALong
by DEXWireNews
MGNX a biotech company gets new "Outperform" LONGMGNX as a biotech company makes antibodies against certain cancers. The antibody is tagged to chemotherapy molecules and then heads off looking for cancer cells to which it has a strong affinity. So much for the science. MGNX just got upgraded and the new target is $ 16.00 about 25% upside. Biotech and healthcare are projected hot sectors this year. On the 15 minute chart price jumped about 12% in the past week and bounced down toward the anchored mean VWAP and is well situated for a long entry. the dual TF RSI indicator shows both lines crossing the 50 level in early bullish momentum off the bounce. It is continually hitting new past year highs at a great trend angle and is on pace to hit 400% for an annual return. There is no option play here as the volume is minimal and liquidity is absent. The all-time high is about $32 so there is plenty of room above the analyst's target over the long term. Price has moved 12X the S & P YTD certainly a sign of relative strength.
NASDAQ:MGNXLong
by AwesomeAvani
1
Moderna’s Stock Boosted by Data From Trial of Melanoma TreatmentModerna Inc.’s stock soared 14% early Thursday to early Friday after the biotech company and partner Merck & Co. announced positive data from a trial of Moderna’s mRNA-4157 in combination with Merck’s blockbuster cancer drug Keytruda in patients with resected high-risk melanoma (stage III/IV). The companies said that after about three years, the combination reduced the risk of recurrence or death by 49% in a Phase 2 trial and the risk of distant metastasis or death by 62%, as compared with Keytruda alone. “As we continue to follow participants in the Keynote-942/mRNA-4157-P201 study, we are excited to see such a robust clinical benefit with mRNA-4157 (V940) as adjuvant treatment in combination with Keytruda in people with resected high-risk melanoma,” said Kyle Holen, senior vice president and head of development in therapeutics and oncology at Moderna. “These data add another positive analysis to the multiple endpoints and subgroups previously assessed in this study,” he said. Technical Analysis NASDAQ:MRNA reached its 1 Month High on the 14th December, 2023 siting the stocks responds to the Positive Data from the Trial of Melanoma Treatment. Moderna’s stock has fallen 50% to date in 2023, while the S&P 500 has gained 22.6%. Although NASDAQ:MRNA is trading near the bottom of its 52-week range and below its 200-day simple moving average, the stock is likewise showing signs of a continual trend which is poise to set foot on a new Resistance level.
NASDAQ:MRNALong
by DEXWireNews
2
SESN Sesen Bio Selloff | Buy the dip???SESN received a preapproval for the dug, Vicineum, but not in its present form. and the market overreacted to it. sold at market prices. and the price went down to 0.86usd, its strongest support. The FDA has determined that it cannot approve the BLA for Vicineum in its present form and has provided recommendations specific to additional clinical/statistical data and analyses in addition to Chemistry, Manufacturing and Controls (CMC) issues pertaining to a recent pre-approval inspection and product quality. (businesswire.com) And they don`t have only one product in their pipeline. Sesen Bio focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. (marketbeat.com) On 8/11/2021 BlackRock Inc. reported 10,657,812 for a total of $49.24M +264.7% increase and an ownership in SESN of 6.150% On 8/13/2021 Vanguard Group Inc. reported 8,503,982 for a total of $39.29M +18.2% increase and an ownership in SESN 4.339% My price target is between 2.7 to 3.2usd. I look forward to read your opinion
SLong
by TopgOptions
BYSI BeyondSpring Price TargetBYSI BeyondSpring drug, plinabulin, increased overall survival and improved other measures of disease while staving off a dangerous side effect associated with Chemotherapy. BeyondSpring is preparing to ask for plinabulin approval in the U.S. and China. On 8/4/2021 J. Pantginis from HC Wainwright brokerage Upgraded BYSI BeyondSpring from Neutral to Buy giving a Price Target of $100.00 My price target is the all time high resistance of 48usd until we hear some news from the FDA.
NASDAQ:BYSILong
by TopgOptions
Ultimovacs ASCO 2021 60% ORR 30% CR #cancervaccineUltimovacs’ UV1 in combination with pembrolizumab shows 60% Objective Response Rate in advanced melanoma Phase I data • UV1/pembrolizumab results in 30% complete responses plus 30% partial responses • Good safety and tolerability profile supports use of UV1 in combination treatments • Data to be presented at ASCO and abstract to be discussed in webcast on May 20, 2021 Oslo, 19 May 2021: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced that its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab, demonstrated a 60% objective response rate (ORR) in metastatic malignant melanoma. All patients have been observed for at least 18 months and median observation time is 21 months. The results will be presented as an online poster at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. The 60% ORR (6 complete responses (CR); 6 partial responses (PR) from a 20-patient cohort) with 30% CR, clearly exceeds the response rate for pembrolizumab alone in advanced melanoma (33-37% ORR and 5-12% CR)*. The median progression-free survival for the UV1/pembrolizumab combination in the study was 18.9 months compared with 5.5-11.6 months* for pembrolizumab alone in advanced melanoma. The overall survival was 80%, with the median overall survival yet to be reached after 21-months of follow-up. “These very strong and exciting data further strengthen the foundation for our broad Phase II clinical program for UV1,” said Jens Bjørheim, Chief Medical Officer at Ultimovacs. “To show this level of beneficial clinical response while being safe and well-tolerated in combination with pembrolizumab underscores our development strategy to show that UV1 can provide a significant increase in therapeutic effect in a broad range of indications and combinations.” The rationale for the use of UV1 is that patients with advanced malignant melanoma often lack the relevant T cells to obtain durable benefits from the use of pembrolizumab alone. UV1 expands T cells that have the potential to increase the breadth and diversity of the immune response towards all parts of the tumor. The data comes from Ultimovacs’ open-label Phase I study (NCT03538314) and will be shown as a poster presentation at ASCO, to be held virtually Friday, June 4, 2021 through Tuesday, June 8, 2021. The data also shows that the UV1/pembrolizumab combination is well tolerated, with adverse events largely restricted to low grade effects, mainly injection site reactions. “These data reinforce our conviction that UV1 can play a transformative role in the treatment of conditions such as malignant melanoma,” said Carlos de Sousa, CEO of Ultimovacs. “It suggests that UV1 in combination with checkpoint inhibitors like pembrolizumab can mobilize the immune system to fight cancer. This is very encouraging for melanoma patients and for those involved with the roll-out of Ultimovacs’ broader programs in solid cancers.” Webcast A corporate webcast will be held on Thursday 20 May 2021, 10:00 CEST. Carlos de Sousa, CEO of Ultimovacs and Jens Bjørheim, CMO, will discuss the ASCO abstract. It will be possible to submit written questions during the presentation. The webcast will be available subsequently on the company website;
ULong
by savepiginvest
ODT Odonate Therapeutics all time low! Buy oportunity?Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the development of tesetaxel and will wind down the operations of the Company. As of December 31, 2020, Odonate had $157.3 million in cash, compared to $180.5 million as of December 31, 2019. (businesswire.com) ODT Odonate Therapeutics MARKET CAP 147.784M That`s less than its cash balance! The indicators showed a sell signal just before the selloff. I know it`s a speculative buy, buy it worth the risk? What is your opinion? If you are also interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
OLong
by TopgOptions
2
HALBERD CORPORATION· Current Price – $0.0419 · Best Case Scenario PT over 1$ · Market Cap – $11 million · Debt – 0 Halbert Corporation Are a biomedical company with a clear aim to revolutionize the world of medicine. They are working towards a creation of variety of antibodies and treatments using extracorporeal techniques (outside of body). They believe they have the technology to cure diseases like, Covid-19, PTSD, Cancer, CTE, tuberculosis, malaria, strokes and heart attacks, blood sepsis, Alzheimer’s Disease. In the last 8 months they have secured 7 provisional patents (which give the global rights) to technology of treating severe Covid-19 patients, Covid-19 nasal spray, antibody cocktail to boost immune system against Covid - 19 and recently developed two new antibodies that no other big pharma has, which allows them detect Covid-19 in matter of minutes using saliva or blood samples. Furthermore, are working with $GRPS to develop anti-addiction patches (alcohol, drugs, nicotine). To achieve their further goals they have carefully selected to partner with Arizona State University (who have won the first place in innovation for the last 6 years going in the USA, higher than MIT or Stanford). This partnership has already delivered amazing milestones and they are already working towards filing for new joint provisional patents. Halbert has 0 debt, yes ZERO and been receiving funding in 2 million chunk donations due to promising results. Halberd’s corporate charter also prohibits them from issuing any kind of convertible financial instrument, debt or preferred stock, however the corporation shall be able to issue warrants or options. Management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment. Furthermore, the ultimate catalyst, which seems quite likely is for Halbert to partner or licence their technology to one of the big pharma as the CEO, William has mentioned so on multiple occasions. In the past, he has been approached by the big pharma (Pfizer and Novartis), and hopes the same will happen with their revolutionary technology. Issued Patents 2014 - Sequential Extracorporeal Treatment of Bodily Fluids 2015 - Utilization of Stents for the Treatment of Blood Borne Carcinomas Provisional Patents 11/2020 - Fluorescent Antibody’s in Covid-19 Detection & Treatment 10/2020 - Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus). 10/2020 - Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus 09/2020 - Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans 04/2020 - Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus 04/2020 - Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients 03/2020 - Method for Treating and Curing Covid-19 Infection Future Patents During podcasts and interviews the CEO said he will announce another 2 patents soon. They are waiting to achieve provisional status to ensure the technology is safe. Further patents are in the pipeline as CEO’s devised a strategy to secure as many patents as they can, of which they could then either licence or partner on developing on joint ventures with big pharma. Upcoming Catalyst 2021 · 2 patent provisional applications yet to be announced · Development of antibody cocktail vitamins to boost immune system against Covid-19 (Q2 launch and start to generate revenue) · Development of Covid-19 Nasal Spray · Commercial development of Covid-19 test using saliva or blood (takes only a minute no nasal swap which is uncomfortable) · Patent Licencing to other pharma companies – they produced antibodies that are stronger than some of the big pharma · Partnerships and joint ventures with other organizations · Discovery of new treatments and patent fillings · Further development of extracorporeal technology to treat cancer, PTSD, Alzheimer’s, blood sepsis, CTE · Anti-addiction patches Sociability Factor In penny stock market, especially during current times (rise of social media and social traders) the CEO’s or the organization being sociable, sharing achievements, milestones, ethos and so on can have a massive impact on the share value. In this regard, Halberd’s corporation in my view would score high points. They tend to release anywhere between 2/5 press releases a month in which various milestones would be announced via text, video interviews or podcasts. Senior Leadership Team The CEO’s aim was to ensure that they develop a very cohesive team of talented people to achieve greatness. Here below I have listed a few KEY members including bio snapshots. Business Advisory Board The CEO – based on the videos and podcasts that are available (6+) of William A. Hartman sounds very ambitious and driven on a mission to be the best in the industry and revolutionize medicine. He believes Halberd corporation share value should be worth $1 per share. This may sound like very ambitious venture for some, however, let us not forget he founded and headed separate business group within TRW Automotive with plants in the U.S., Mexico and Europe that produced combined annual sales of $1.3 Billion – this shows extreme capability. He has also worked as COO for Nanologix, Inc, President and CEO of Premier Biomedical. I would recommend checking out any of his interviews to feel his passion. Carl Eller - retired NFL Pro Football Hall of Famer, and President of the NFL Retired Players Association, was drafted in 1964 as the league’s 6th pick overall by the Minnesota Vikings, he became a major factor as a defensive end with the unit known as the “Purple People Eaters.” Eller became a six-time Pro Bowl player who appeared in four Superbowls and is currently focused on helping former players transition into retirement. Alec Torelli - is an entrepreneur, author, motivational speaker and professional poker player who has worked with various companies to apply his life experiences/lessons from poker, in a practical manner, to carry out their corporate visions, increase sales and/or improve service delivery while creating meaningful lives for their employees. Scientific Advisory Board Mitchell S. Felder, MD - is a prolific inventor. He is a Board Certified Neurologist and former CEO, President, Chairman and founder of Infectech and Nanologix, and currently serves as Locum Tenens Attending Neurologist with UPMC Pennsylvania Dr. Felder has authored or co-authored six publications, three studies and has currently 21 issued patents. Dr. Felder was the Acting Chief of the Department of Neurology, Sharon Regional Health System from 1989 until 2001. Dr. Felder served as the Acting Chief of the Department of Neurology at the William Beaumont Army Medical Center in 2011. Dr. Qiang (Shawn) Chen, who is the Principal Investigator at ASU, in charge of the research and development for Halberd Corp: Take a look at his research projects over the last 4-5 years and you see why this HALB/ASU cooperation is a marriage made in heaven. Only weeks ago, Halberd signed another R&D-agreement with GreenBioAZ inc, it's a start up from Arizona State University and will do research for Halberd's radiofrequency technology. Dr. Chen is CEO of GreenBioAZ Patricio Reyes, MD, FAAN - a board certified neurologist and neuropathologist, and Chief of Neurology/TBI/Alzheimer’s Disease/Cognitive Disorders at the VA Medical Center in Phoenix, Arizona and is a Board Member of the Retired National Football League Players Association. Dr. Reyes is a board member, and former Chair of the Education Committee and 2009 Distinguished Educator of the Association of Ringside Physicians. HALB has access to the VA Hospital Group because of Dr. Reyes. Timeline of Key Press Releases I have gone through the list of all of their press releases (they post regularly) and compiled key updates here below: April 6, 2020 - Halberd announces agreement to retire 192,000,000 outstanding common shares and reduced authorized shares of common stock to 1,000,000,000. April 8, 2020 – Halberd, Premier Biomedical ($BIEI) and Gold River Productions ($GRPS) announce the signing of a multi-faceted agreement for ongoing R&D into a potential treatment and cure for Covid-19 as well as development of Premier’s Anti-Addiction Patch. July 1, 2020 - Halberd establishes United Kingdom subsidiary to facilitate access to European research facilities and markets to establish a global footprint. July 13, 2020 - Halberd’s corporate charter prohibits it from issuing any kind of convertible financial instrument, debt, or preferred stock. August 4, 2020 - Halberd secures $2 Million for Covid-19 Research August 31, 2020 - Halberd signed an agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments. September 21, 2020 - Covid-19 Research Program Progress – Successful Covid Spike Protein Disease Antigen September 24, 2020 - Successful creation of a fluorescent antibody, that will help them create a rapid Covid-19 test using saliva or a drop of blood. This approach will allow for accurate test results in a matter of minutes – believe travel industry may benefit from this approach. October 8th, 2020 – CEO’s letter of updates and accomplishments October 13, 2020 – Halberd and ASU Develop Antibody Against Covid-19, pursuing new joint patent. October 19, 2020 – in process to filing a new joint patent with AUS for creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19. This protein will allow extremely rapid identification of the Covid-19 virus in nasal mucus, saliva, and blood. October 29, 2020 – Strategic plan curing blood sepsis, Alzheimer’s Disease, Heart Attack and Stroke using extracorporeal process November 12, 2020 – Patent pending for Covid-19 detection test from saliva or blood in minutes. December 1, 2020 – Halberd re-organizes advisory board. December 17, 2020 - Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19 December 23, 2020 - Halberd Produces a Second Monoclonal Antibody Against Covid-19 Spike Protein – “Mathematically speaking, if each is 90% effective independently, then, absent any interrelationship of the two applications, the combination should be 99% effective. In other words, the prospect of obtaining diagnostic test false positives or false negatives is substantially reduced when antibodies work in tandem” January 4, 2021 - Halberd Corporation 2020 Year End CEO Letter, looking forward to 2021 January 14, 2021 - Halberd Develops Medication to Boost Immune System Against Covid-19 February 16, 2021 - Halberd has engaged GreenBioAZ to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease. March 2, 2021 - Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater - “We are excited about the progress being made in developing Halberd’s effective proprietary antibodies against Covid-19. These results put our antibody in the same realm of effectiveness as the best-known competitive SARS-COV-2 antibodies. Since posting links may take an excessive amount of space here, you can find all the press releases here and search by date, plenty more to see that are not included in my post - Hope people found this helpful and I look forward to seeing what the future holds for $HALB!
OTC:HALBLong
by headdeveloper33
1
Why SELLAS Life Sciences Is Surging Premarket?Why SELLAS Life Sciences Is Surging Premarket? SELLAS Life Sciences is captivating investors thanks to its late-stage cancer vaccine Thanks to some news in December in the biopharma space, SLS stock is racing higher. So what was that news? And what else do you need to know? its leading candidate Galinpepimut-S is making its way through Phase 3. This immunotherapy targets the Wilms Tumor 1, which is the leading cancer antigen. Essentially, the company believes that this therapy, which is given via vaccine, reduces the immune response in a patient and has the ability to delay the relapse of cancer. Although SELLAS Life Sciences is testing it for a variety of cancers, it is currently in Phase 3 trials for acute myeloid leukemia. This lead candidate is where the massive move in SLS stock comes from. Importantly, SELLAS Life Sciences had some big news of its own in december. While its leading immunotherapy candidate remains in clinical trials, it entered a license agreement with China-based 3D Medicines. Through this deal, 3D Medicines will handle developing and commercializing Galinpepimut-S in mainland China, Hong Kong, Taiwan and Macau. According to a company press release, this could net $202 million in license fees for SELLAS. It also could bring an upfront payment of $7.5 million sometime this quarter. it looks like another company is responsible for the move in SLS stock. What do I mean? Well, in december we saw a major rally in Greenwich LifeSciences (NASDAQ:GLSI). Ahead of a conference, the company shared promising Phase 2b data on its breast cancer immunotherapy. Importantly, Greenwich LifeSciences is evaluating GP2 as a therapy for patients who have already undergone surgery for breast cancer. And according to the report yesterday, GP2 has reduced the recurrence rate of cancer in trial participants to 0%. How does this tie into SELLAS Life Sciences? Well, GP2 and Galinpepimut-S are both unique immunotherapies that rely on vaccination as a delivery method. Essentially, both treatments are cancer vaccines. Both treatments are also quite innovative, representing potential advancements in the realm of cancer care. This means that with a more than 2,000% rally from GLSI stock, many investors may be rooting for the same with SLS. Remember though, this is a tiny company that must continue to navigate clinical trials. Keep an eye on SLS stock, but proceed with caution.
NASDAQ:SLS
by AlenCiken
Ultimovacs Announces Updated Positive Results from Phase I TrialOslo, 19 October 2020: Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), today announced five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in patients with non-small cell lung cancer. The results confirm achievement of the primary endpoints of safety and tolerability and indicate encouraging initial signals of long-term survival benefit. "Ultimovacs has established a growing body of clinical data demonstrating a strong safety and tolerability profile for UV1 and a range of preliminary efficacy signals in several cancer indications, all of which supports the further development of our proprietary cancer vaccine candidate," stated Carlos de Sousa, Chief Executive Officer at Ultimovacs. "The long-term follow-up results announced today demonstrate that treatment with UV1 is safe both at the time of administration and throughout the follow-up period of at least 5 years. Non-small cell lung cancer highly expresses telomerase and remains an indication in great need of new treatment options for patients." In the study, a total of 18 non-small cell lung cancer patients whose disease had not progressed after receiving at least 2nd line treatment with chemotherapy were enrolled to receive UV1 monotherapy as maintenance treatment. Outcomes of the study included the safety and tolerability of UV1 as well as initial signs of clinical response. As per the cut-off date of June 2020, every patient in the trial reached at least 60-months of follow-up post treatment with UV1. At the five-years landmark, the Overall Survival (OS) rate was 33% and median Progression Free Survival (mPFS) was 10.7 months. Throughout the follow-up period, none of the patients experienced unexpected safety issues related to UV1. Further, none of the patients alive after 5 years have received other immunotherapy after the vaccination with UV1. "At the time of the study initiation, there were no checkpoint inhibitors available for treatment of this patient population. For patients that received a second-line of chemotherapy the expected 5-year survival rate was less than 5 percent," stated Jens Bjørheim, Chief Medical Officer at Ultimovacs. "While our Phase I study is non-randomized and conducted in a small population, it is promising to see that UV1 was safe and well-tolerated and that using UV1 as a maintenance therapy could potentially provide benefit to patients in need of novel approaches." Ultimovacs presented 48-months of follow-up data at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting in November of last year.
ULong
by savepiginvest